Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Tissue-Based Heart Valves Better for the Middle-Aged

By HospiMedica International staff writers
Posted on 26 Jan 2016
Patients between 40 and 70 years of age who undergo aortic valve replacement (AVR) may fare better with tissue-based valves rather than metal-based ones, according to a new study.

Researchers at the University of Sydney (Australia; sydney.edu.au) and Royal Prince Alfred Hospital (Sydney, NSW, Australia) conducted a database search and identified 13 studies comparing mechanical and bioprosthetic valves in AVR patients aged 40 to 70 years. More...
The results revealed that 15-years post-surgery, no difference was found in survival, stroke rate, or rate of endocarditis among patients with either valve; however, each patient group developed a different set of complications.

Patients with bioprosthetic valves were twice as likely as mechanical valve patients to need re-operation due to worn-out valves, while patients with mechanical valves were twice as likely to experience a major bleeding event or a blood clot. Because patients with major bleeding had a significant increase of death compared to those needing reoperation, the researchers concluded that bioprosthetic valves should strongly be considered for patients in this age group, though valve choice should be individualized for each patient. The study was published on January 12, 2016, in the Annals of Thoracic Surgery.

“We combined the best available evidence comparing mechanical valves versus bioprosthetic valves to determine the risks and benefits to patients following surgery, depending on the type of valve they received,” said lead author James Wu, BMusStudies, of the University of Sydney. “We hope that our results can give future patients needing AVR more information to help them choose the appropriate replacement valve for their condition.”

“This is a complex decision that requires up-to-date evidence. There are options to reduce the bleeding risk of mechanical valves, so, ideally, a discussion with both the surgeon and cardiologist is warranted to take into account an individual's circumstances,” concluded senior author Paul Bannon, MBBS, PhD.

Mechanical valves are the most long-lasting type of replacement valve, but patients will usually require blood thinners to stop clots from forming, as they can lodge in valve flaps or hinges which can cause a malfunction or form emboli. Bioprosthetic tissue can last 10–20 years, but usually do not require long-term use of medication. On the other hand, a young person with a bioprosthetic valve replacement, the need for additional surgery or another valve replacement later in life is highly likely.

Related Links:

University of Sydney
Royal Prince Alfred Hospital



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.